INTRODUCTION

Total knee arthroplasty (TKA) is one of the most common orthopedic surgical procedures whereby the diseased knee joint is replaced with artificial material. This procedure accounts for more than one million cases annually in the U.S., and a dramatic increase in the number of TKAs will likely be seen.1 Patients undergoing this procedure are at high risk of venous thromboembolic events (VTEs), including deep venous thrombosis (DVT) and pulmonary embolism (PE), post-operatively.2-7 VTE after TKA is of great concern because of the associated increases in morbidity and mortality reported in the literature.2,5,6 To prevent VTE after TKA, administration of prophylaxis is recommended by both the American Academy of Orthopaedic Surgeons and the American College of Chest Physicians.8,9

Prophylactic strategies to prevent VTE after primary TKA vary widely and are influenced by surgeon experience, current research, and historical precedent. Aspirin, enoxaparin, apixaban, rivaroxaban, and coumadin are the most common methods of DVT chemoprophylaxis used by orthopedists.3,5,10-16 However, anticoagulation after TKA can pose unique challenges because anticoagulation medications must balance the reduction in blood clot formation, with the risk of post-operative bleeding, hematoma formation, revision surgery, and infection.17-19 Despite decades of clinical experience, new technology on implant design, better surgical procedure, improved physical therapy protocol, and hundreds of studies, the ideal method of VTE prophylaxis remains controversial. This has resulted in variability and inconsistency of prophylaxis for TKA patients and a concern that many patients may be left at risk with no prophylaxis or suboptimal prophylaxis. The specific aim of this study was to evaluate the use of different post-operative prophylactic strategies on the rates of symptomatic VTE incidence after primary TKA.

METHODS

Subjects. Institutional Review Board approval was obtained for this study. This retrospective study reviewed the clinical charts of patients (greater than 18 years of age) who had undergone primary TKA procedures from January 2015 through July 2020 from hospitals within a single institution in the Midwest region. Patients who underwent unicompartmental knee arthroplasty, revision knee arthroplasty, same day bilateral TKAs, or had less than 90 days follow-up without any complications were excluded from this study.

Variables. The retrospective chart review gathered patient demographic data including age, gender, body mass index (BMI), surgical date, site of procedure, prophylaxis medication used during inpatient care and outpatient care, amount of medication, length of medication, and length of hospital stay. Post-operative complications included those occurring within 90 days post-operatively including symptomatic VTEs and upper and lower gastrointestinal (GI) bleeding requiring medical attention. Change in management protocols after post-operative complications and mortality also were recorded.

Statistical Analysis. Descriptive statistics of the mean, standard
deviation, range, and percentages were determined for subject demographics, prophylaxis medication used during inpatient care and outpatient care, length of medication, and complications. One-way analysis of variance (ANOVA) with the Least Significant Difference (LSD) multiple comparisons post hoc test method was utilized to determine significant observed differences among different parameters (e.g., age, BMI, length of hospital stay, prophylaxis medication used during inpatient care, and post-operative complications) between the five years. All statistical testing methods were performed using IBM® SPSS Statistics software (version 24.0.0.0; IBM® Corporation, Armonk, NY), and the statistically significant relationships were defined as those with \( p < 0.05 \). Relative risk ratio with 95% confidence interval was utilized to compare complication rates among therapies. A risk ratio greater than 1.0 indicated an increased risk of complication compared among the other therapies.

**RESULTS**

There were 6,440 primary TKA cases identified, with only 5,663 of those cases (2,254 males and 3,409 females) included in this study due to exclusion criteria or incomplete inpatient medication. The mean age was 66 ± 10 years (range: 23 - 96 years) and the mean BMI was 34.1 ± 7.1 kg/m² (range: 17.7 - 79.1 kg/m²). The mean hospital stay was 2.1 ± 1.3 days (range: 0 - 34; Table 1). There were 155 patient deaths recorded in this study, and 10% (n = 15) were within 90 days post-operatively due to natural causes or other medical conditions.

There were 0.9% (n = 50) post-operative complications including symptomatic DVT (0.5%), PE (0.3%), unspecified VTE (0.04%), and upper and lower GI bleeding (0.09%). The mean age for these complication groups was 65 ± 11 years (range: 41 - 83 years) and the mean BMI was 33.6 ± 6.0 kg/m² (range: 22.4 - 50.0 kg/m²). The mean hospital stay for all complication groups was 3.1 ± 2.6 days (range: 1 - 12; Table 1).

There were seven different anticoagulants prescribed as inpatient medication in this study: enoxaparin, rivaroxaban, warfarin, apixaban, aspirin 325 mg, aspirin 81 mg, and heparin (Table 2). Enoxaparin (34% of the patients) was the most frequently used medication for inpatient anticoagulation for DVT chemoprophylaxis. Utilization of rivaroxaban, aspirin 325 mg, aspirin 81 mg, and heparin as inpatient anticoagulation medication were more likely to increase the risk of symptomatic VTE incidence compared to other anticoagulants.

When comparing the yearly breakdown, utilization of enoxaparin as inpatient anticoagulation medication was reduced significantly over the five years (67% vs. 13%, \( p < 0.001 \)), except the years 2018 and 2019 (\( p = 0.61 \)). The other inpatient anticoagulation medications were increased significantly over the years, especially apixaban (6% vs. 49%, \( p < 0.001 \); Figure 1). Average hospital stays were reduced significantly among the years (2.8 ± 1.7 days vs. 1.5 ± 1.0 days, \( p < 0.001 \), except the years 2018 and 2019 (\( p = 0.61 \)). The complication rates were not significantly different across the five years (-1%), except the years 2016 and 2019 (0.4% vs 1.2%, \( p = 0.04 \); Table 3).

The three most common outpatient anticoagulation medications prescribed were apixaban (31%), aspirin 325 mg (38%), and enoxaparin (14%). Of the post-op complications, the most common outpatient medications used were apixaban (26%) and aspirin 325 mg (36%). However, the relative risk ratio results indicating that utilization of warfarin, rivaroxaban, and aspirin 81 mg as outpatient anticoagulation medication were more likely to increase the risk of symptomatic VTE incidence compared to other anticoagulants. The average time of complication detection was 208 ± 211 days (range: 1 - 87 days), and 40% of the complications found occurred after the patient had completed their anticoagulation medication (Table 4).

When comparing the time of complication and length of time on outpatient anticoagulation medication, the results of this study demonstrated that when enoxaparin, rivaroxaban, and apixaban were used as outpatient anticoagulation medications, more than 54% of complication events occurred after the patient had completed their medication (Table 5).

**Table 1. Patient demographics.**

| Variable                      | Overall (N = 5,663) | Complication (N = 50) | DVT (N = 28) | PE (N = 15) | VTE (N = 2) | GI Bleed (N = 5) |
|-------------------------------|---------------------|-----------------------|-------------|------------|------------|-----------------|
| Gender, n (%)                 |                     |                       |             |            |            |                 |
| Female                        | 3,409 (60%)         | 30 (60%)              | 14 (50%)    | 12 (80%)   | 2 (100%)   | 2 (40%)         |
| Male                          | 2,254 (40%)         | 20 (40%)              | 14 (50%)    | 3 (20%)    | -          | 3 (60%)         |
| Age, mean years ± SD (range)  | 66 ± 10 (23 - 96)   | 65 ± 11 (41 - 83)     | 65 ± 12 (41 - 82) | 63 ± 10 (47 - 77) | 70 ± 4 (67 - 72) | 73 ± 11 (56 - 83) |
| BMI, mean kg/m² ± SD (range)  | 34.1 ± 7.1 (17.7 - 79.1) | 33.6 ± 6.0 (22.4 - 50.0) | 32.2 ± 5.1 (22.4 - 49.0) | 35.5 ± 6.1 (23.8 - 43.9) | 41.0 ± 12.6 (32.1 - 50.0) | 32.9 ± 5.7 (26.8 - 40.3) |
| Site of Procedure, n (%)      |                     |                       |             |            |            |                 |
| Left                          | 2,743 (48%)         | 25 (50%)              | 15 (54%)    | 8 (53%)    | -          | 2 (40%)         |
| Right                         | 2,920 (52%)         | 25 (50%)              | 13 (46%)    | 7 (47%)    | 2 (100%)   | 3 (60%)         |
| Hospital stay, mean days ± SD (range) | 2.1 ± 1.3 (0 - 34) | 3.1 ± 2.6 (1 - 12) | 2.3 ± 1.7 (1 - 9) | 4.7 ± 3.7 (1 - 12) | 2.5 ± 0.7 (2 - 3) | 2.8 ± 1.1 (1 - 4) |
Table 2. Inpatient medication effects on complications.

| Inpatient Medication | Overall (N = 5,663) | Complication (n = 50) | Relative Risk Ratio (RR) | 95% RR Confidence Interval | DVT (n = 28) | PE (n = 15) | VTE (n = 2) | GI Bleed (n = 5) |
|----------------------|---------------------|-----------------------|-------------------------|-----------------------------|-------------|------------|-------------|----------------|
| Enoxaparin           | 1,941 (34%)         | 16 (32%)              | 0.9                     | (0.6 - 1.6)                 | 9 (32%)     | 4 (27%)    | 1 (50%)     | 2 (40%)        |
| Rivaroxaban          | 484 (9%)            | 6 (12%)               | 1.5                     | (0.4 - 3.4)                 | -           | -          | -           | -              |
| Warfarin             | 182 (3%)            | 1 (2%)                | 0.6                     | (0.1 - 4.4)                 | -           | 1 (7%)     | -           | -              |
| Apixaban             | 1,785 (32%)         | 10 (20%)              | 0.5                     | (0.5 - 1.1)                 | 2 (7%)      | 4 (27%)    | 1 (50%)     | 3 (60%)        |
| Aspirin (325 mg)     | 1,140 (20%)         | 13 (26%)              | 1.4                     | (0.5 - 2.6)                 | 9 (32%)     | 4 (27%)    | -           | -              |
| Aspirin (81 mg)      | 122 (2%)            | 2 (4%)                | 1.9                     | (0.3 - 7.7)                 | 1 (4%)      | 1 (7%)     | -           | -              |
| Heparin              | 9 (0.2%)            | 2 (4%)                | 26.2                    | (0.3 - 91.8)                | 1 (4%)      | 1 (7%)     | -           | -              |

Table 3. Yearly comparison of complication to hospital stay time and complication rate.

|                          | Year 2015 (n = 1,020) | Year 2016 (n = 1,089) | Year 2017 (n = 1,094) | Year 2018 (n = 1,203) | Year 2019 (n = 1,032) |
|--------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|
| Hospital stay (days)     | 2.8 ± 1.7 (1 - 34)     | 2.6 ± 1.2 (1 - 20)     | 2.2 ± 1.0 (0 - 10)     | 1.5 ± 1.1 (0 - 14)     | 1.5 ± 1.0 (0 - 9)      |
| Complication             | 10 (1.0%)              | 4 (0.4%)               | 8 (0.7%)               | 11 (0.9%)              | 12 (1.2%)              |

Note: Year 2020 was excluded due to only having four months of data.

Figure 1. Yearly comparison of inpatient medications.
**Table 4. Outpatient medication effects on complications.**

| Outpatient Medication | Overall (N = 5,663) | Complication (n = 50) | Relative Risk Ratio | 95% RR Confidence Interval | DVT (n = 28) | PE (n = 14) | VTE (n = 2) | GI Bleed (n = 5) |
|-----------------------|---------------------|-----------------------|---------------------|---------------------------|-------------|-------------|-------------|----------------|
| Enoxaparin            | 800 (14%)           | 7 (14%)               | 1.0                 | (0.5 - 2.2)               | 3 (11%)     | 1 (7%)      | 1 (50%)     | 2 (40%)        |
| Rivaroxaban           | 266 (5%)            | 3 (6%)                | 1.3                 | (0.3 - 4.1)               | 3 (11%)     | -           | -           | -              |
| Warfarin              | 284 (5%)            | 5 (10%)               | 2.1                 | (0.4 - 5.3)               | 1 (4%)      | 4 (27%)     | -           | -              |
| Apixaban              | 1,766 (31%)         | 13 (26%)              | 0.8                 | (0.5 - 1.5)               | 5 (18%)     | 5 (33%)     | 1 (50%)     | 2 (40%)        |
| Aspirin (325 mg)      | 2,167 (38%)         | 18 (36%)              | 0.9                 | (0.6 - 1.6)               | 14 (50%)    | 3 (20%)     | -           | 1 (20%)        |
| Aspirin (81 mg)       | 295 (5%)            | 4 (8%)                | 1.6                 | (0.4 - 4.4)               | 2 (7%)      | 2 (13%)     | -           | -              |

**Time to Complication**

- 21 ± 21 (1 - 87)
- 14 ± 14 (2 - 54)
- 51 ± 16 (40 - 62)
- 19 ± 19 (1 - 50)

**Complication vs. on/off regimen**

| On | Off |
|----|-----|
| On | -   | 30 (60%) | - |
| Off| -   | 20 (40%) | - |

**Table 5. Outpatient medication regimen on complications.**

| Overall complication (N = 50) | Time on Outpatient Medication (Days) | Time of Complication (Days) | On Regimen | Off Regimen |
|------------------------------|-------------------------------------|----------------------------|------------|-------------|
| Enoxaparin (n = 7)           | 8.4 ± 1.7 (7 - 12)                  | 16.0 ± 15.8 (1 - 40)       | 3 (43%)    | 4 (57%)     |
| Rivaroxaban (n = 3)          | 11.0 ± 2.7 (9 - 14)                 | 39.3 ± 19.7 (26 - 62)      | -          | 3 (100%)    |
| Warfarin (n = 5)             | 50.0 ± 45.8 (0 - 90)                | 8.6 ± 7.8 (2 - 22)         | 4 (80%)    | 1 (20%)     |
| Apixaban (325 mg) (n = 13)   | 19.1 ± 17.7 (9 - 60)                | 25.9 ± 23.2 (2 - 75)       | 6 (46%)    | 7 (54%)     |
| Aspirin (325 mg) (n = 18)    | 26.2 ± 7.8 (6 - 32)                 | 22.1 ± 24.2 (2 - 87)       | 13 (72%)   | 5 (28%)     |
| Aspirin (81 mg) (n = 4)      | 30.0 ± 0.0 (30 - 30)                | 8.3 ± 4.2 (4 - 14)         | 4 (100%)   | -           |

**DISCUSSION**

The specific aim of this study was to evaluate the use of different post-operative prophylactic strategies on the rates of symptomatic VTE incidence after primary TKA. Complication rates were not significantly different across the five years despite which inpatient or outpatient anticoagulation prophylaxis was used. Forty percent of the complications took place after patient had completed their anticoagulation medication, and when looking specifically at enoxaparin, rivaroxaban, and apixaban as outpatient prophylaxis, more than 54% of complications occurred after the patient had completed their medication.

Patients undergoing TKA are at high risk of VTE if they do not receive anticoagulation as it is considered as the third most frequent cause for hospital readmission after TKA.20 There is considerable debate regarding the appropriate post-operative prophylactic agent for patients undergoing primary TKA,21-23 with many surgeons making decisions based on anecdotal evidence and historical precedent. As VTE is an uncommon event with reported rates of symptomatic VTEs within 90 days of TKA at less than 2%,24,25 and the mortality rates from VTE following lower limb arthroplasty low (less than 1%),23-28 it is difficult to acquire sufficient statistical power to discern differences between agents.

Over the five-year study period, there was a transition from using enoxaparin to oral anticoagulation therapy such as apixaban, rivaroxaban, and aspirin. At the end of the study period, some surgeons’ preference was to prescribe all their patients one of the direct oral inhibitors (e.g., apixaban, rivaroxaban), whereas others were risk stratifying based on patients’ history. Due to this study being a retrospective review, there was no standardization of medication or length of time. Patients that were on anticoagulation before the procedure also were restarted on their previous regimen after surgery.

Two previous meta-analyses found that low-dose aspirin has a similar efficacy in the prevention of VTE when compared to enoxaparin.29-31 Recently, there has been more literature comparing low dose aspirin to high-dose aspirin. In a study by Faour et al.,32 low-dose aspirin was found to be as efficacious to high-dose aspirin in the prevention of VTE following TKA. In another study by Parvizi et al.,33 the efficacy and adverse event profiles of low-dose (81 mg twice daily) versus high-dose aspirin (325 mg twice daily) regimens were examined.
high-dose aspirin (325 mg twice daily) regimens were examined for patients undergoing total hip and knee arthroplasty and they also found that low dose aspirin was as efficacious to high-dose aspirin in the prevention of VTE. A meta-analysis of randomized controlled trials comparing dabigatran, rivaroxaban, apixaban, and enoxaparin reported incidence of symptomatic VTE as 0.7%, 0.5%, 0.5%, and 0.8%, respectively. None of these studies mentioned compared prophylaxis regimens in patients with known hypercoagulable risk factors such as those with inherited blood clotting disorders, history of previous VTE, obesity, malignancy, estrogen therapy, and varicose veins and increased age.

One result of this study captured VTEs occurred at an average of 20 days after discharge, and 40% of those patients who had completed their anticoagulation medication at the time of VTE complication. Specifically, the average length of apixaban, rivaroxaban, and enoxaparin dosing were 17, 10, and 8 days, respectively, while 54% of the apixaban, 100% of the rivaroxaban, and 57% of the enoxaparin post-op symptomatic VTEs occurred after medication completion. These findings were similar to a study by Warwick et al. in 2007, where they found that mean times to VTE after TKA was 9.7 days (SD 14.1 days), but 27% of patients who received the recommended forms of prophylaxis were no longer receiving it after 7 days. Current treatment guidelines for patients following TKA recommended the routine administration of a prophylactic anticoagulant for at least 10 days after the operation.

The American Academy of Orthopaedic Surgeons (AAOS) and the American College of Clinical Pharmacy (ACCP) guidelines for VTE prophylaxis for patients undergoing elective TKA also stated that the duration must be at least 10 to 14 days, and up to 35 days regardless of the medication being used. This indicated it was likely some complications could have been avoided by extending the duration of the medications.

One possibility for the average time to VTE to occur after average medication completion could be due to a rebound hypercoagulable effect. In 2018, Li et al. reported that although a rebound effect is controversial, physicians should be aware of the possibility. The mechanism behind this rebound hypercoagulable phenomenon after discontinuation is uncertain. It has been suggested for rivaroxaban that decreased plasma concentration after its discontinuation results in loss of prothrombinase/factor Xa inhibition at the thrombotic sites, thus leading to prothrombotic activity. Another possibility is the anticoagulation medications were masking the symptoms of the VTE or preventing it from enlarging. Often DVTs are created intraoperative, confirmed by venographic and leg-scanning studies, but are asymptomatic or silent until they can enlarge due to prolonged impairment of venous function, sustained hypercoagulability, or impairment of the endogenous anticoagulant systems.

Limitations. This study had certain limitations. First, a small sample size of post-operative complications found made applying tests of significance to certain variables difficult. A total of 3,400 patients would afford an adequate trial at 95% power and 5% significance, assuming a baseline symptomatic VTE event rate of 1%. Second, this study was a retrospective chart review study that introduced the possibility of selection and/or observation bias, as it was neither randomized nor blinded. Third, patient compliance (or lack thereof) to the post-operative prophylactic regime was not available. Fourth, the information in this study was limited to the specified time within a single institution and there is a possibility of under-reporting that may have played a role, as many DVTs are diagnosed in the outpatient clinic or in the community. Fifth, minor bleeding complications, such as surgical site hematoma and post-operative transfusions, were not recorded in a consistent manner, therefore not included in this study. Sixth, medications purchased over the counter (e.g., aspirin) or provided as samples by physicians were not available in the recorded data. Lastly, a power analysis was not performed since the data were reviewed retrospectively. Further evaluation in a larger randomized controlled study is required to support the findings of this study. The plan is to use these data and perform a quality improvement project to standardize prophylactic anticoagulation strategies after primary TKA in the future.

CONCLUSIONS

Choice of post-operative prophylaxis agents after primary TKA remains an important issue. The observed incidence of symptomatic VTE events in this study is similar to previous literature, regardless of the type of post-operative prophylaxis regimen prescribed after TKA procedure. A higher rate of VTE incidence was observed after completion of apixaban, rivaroxaban, and enoxaparin therapies, suggesting that a longer treatment course may reduce VTE incidence further. In conclusion, the ultimate choice of prophylaxis remains with the treating physician and his or her unique knowledge of a patient’s medical history, especially for patients with known risk factors for VTEs.

REFERENCES

1. Maradit Kremers H, Larson DR, Crowson CS, et al. Prevalence of total hip and knee replacement in the United States. J Bone Joint Surg Am 2015; 97(17):1386-1397. PMID: 26333733.
2. Pellegrini VD Jr, Donaldson CT, Farber DC, Lehman EB, Evarts CM. The Mark Coventry Award: Prevention of readmission for venous thromboembolism after total knee arthroplasty. Clin Orthop Relat Res 2006; 452:21-27. PMID: 16906107.
3. Lieberman JR, Hsu WK. Prevention of venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg Am 2005; 87(9):2097-2122. PMID: 1640827.
4. Cordell-Smith JA, Williams SC, Harper WM, Gregg PJ. Lower limb arthroplasty complicated by deep venous thrombosis. Prevalence and subjective outcome. J Bone Joint Surg Br 2004; 86(1):99-101. PMID: 14765874.
5. Reitman RD, Emerson RH, Higgins LL, Tarbox TR. A multimodality regimen for deep venous thrombosis prophylaxis in total knee arthroplasty. J Arthroplasty 2003; 18(2):161-168. PMID: 12629605.
6. Kim YH, Kim JS. Incidence and natural history of deep-vein thrombosis after total knee arthroplasty. A prospective, randomised study. J Bone Joint Surg Br 2002; 84(4):566-570. PMID: 12043780.
7. Brokenthal KR, Freedman KB, Lotke PA, Fitzgerald RH, Lonner JH. A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty. J Arthroplasty 2001; 16(3):293-300. PMID: 11307125.
8. Markel DC, York S, Liston MJ Jr, et al. Venous thromboembolism: Management by American Association of Hip and Knee Surgeons. J Arthroplasty 2010; 25(1):3-9.e1-2. PMID: 19837560.
9. Eikelboom JW, Karthikeyan G, Fagel N, Hirsh J. American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: What are the implications for clinicians and patients? Chest. 2009;135(2):513-520. PMID: 19207141.

10. Johanson NA, Lachiewicz PF, Lieberman JR, et al. American Academy
KANSAS JOURNAL of MEDICINE

POST-OPERATIVE PROPHYLACTIC STRATEGIES

continued.

10. Johanson NA, Lachiwicz PF, Lieberman JR, et al. American Academy of Orthopaedic Surgeons clinical practice guideline on prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. J Bone Joint Surg Am 2009; 91(7):1756-1757. PMID: 19571100.

11. Parvizi J, Azzam K, Rothman RH. Deep venous thrombosis prophylaxis for total joint arthroplasty: American Academy of Orthopaedic Surgeons guidelines. J Arthroplasty 2008; 23(7 Suppl):2-5. PMID: 18922368.

12. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl):e278S-e325S. PMID: 22345265.

13. Berend KR, Lombardi AV Jr. Multimodal venous thromboembolic disease prevention for patients undergoing primary or revision total joint arthroplasty: The role of aspirin. Am J Orthop (Belle Mead NJ) 2006; 35(1):24-29. PMID: 16475420.

14. Lotke PA, Loner JM. The benefit of aspirin chemoprophylaxis for thromboembolism after total knee arthroplasty. Clin Orthop Relat Res 2006; 452:175-180. PMID: 16955642.

15. Fitzgerald RH Jr, Sprio TE, Trowbridge AA, et al. Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. J Bone Joint Surg Am 2001; 83(6):900-906. PMID: 11407799.

16. Westrich GH, Haas SB, Mosca P, Peterson M. Meta-analysis of thromboembolic prophylaxis after total knee arthroplasty. J Bone Joint Surg Br 2000; 82(6):795-800. PMID: 10990299.

17. Barrack RL. Current guidelines for total joint VTE prophylaxis: Dawn of a new day. J Bone Joint Surg Br 2012; 94(11 Suppl A):3-7. PMID: 23023369.

18. Pulido L, Ghanem E, Joshi A, Purtill JJ, Parvizi J. Periprosthetic joint infection: The incidence, timing, and predisposing factors. Clin Orthop Relat Res 2007; 22(6 Suppl 2):24-28. PMID: 17823010.

19. Seagroatt V, Tan HS, Goldacre M, Bulstrode C, Nugent I, Gill L. Elective total hip replacement: Incidence, emergency readmission rate, and postoperative mortality. BMJ 1991; 303(6815):1431-1435. PMID: 1773447.

20. Stewart DW, Freshour JE. Aspirin for the prophylaxis of venous thromboembolic events in orthopedic surgery patients: A comparison of the AAOS and ACCP guidelines with review of the evidence. Ann Pharmacother 2013; 47(1):63-74. PMID: 23324504.

21. Anderson FA Jr, Huang W, Friedman RJ, et al. Prevention of venous thromboembolism after hip or knee arthroplasty: Findings from a 2008 survey of US orthopedic surgeons. J Arthroplasty 2012; 27(5):659-666.e5. PMID: 22035977.

22. Knesek D, Peterson TC, Markel DC. Thromboembolic prophylaxis in total joint arthroplasty. Thrombosis 2012; 2012:837896. PMID: 23029611.

23. Quinlan DJ, Eikelboom JW, Dahl OE, Eriksson BI, Sidhu PS, Hirsh J. Does “excessive” anticoagulation predispose to perioperative infection? J Arthroplasty 2007; 22(6 Suppl 2):24-28. PMID: 17823010.

24. Howie C, Hughes H, Watts AC. Venous thromboembolism associated with hip and knee replacement over a ten-year period: A population-based study. J Bone Joint Surg Br 2005; 87(12):1675-1680. PMID: 16326885.

25. Poultisides LA, Gonzalez Della Valle A, Memtsoudis SG, et al. Meta-analysis of cause of death following total joint replacement using different thromboprophylaxis regimens. J Bone Joint Surg Br 2012; 94(1):113-121. PMID: 22219258.

26. Cusick LA, Leverland DE. The incidence of fatal pulmonary embolism after primary hip and knee replacement in a consecutive series of 4233 patients. J Bone Joint Surg Br 2009; 91(5):645-648. PMID: 19407300.

27. Petersen AB, Mehnert F, Sorensen HT, Emmeluth C, Overgaard S, Johnsen SP. The risk of venous thromboembolism, myocardial infarction, stroke, major bleeding and death in patients undergoing total hip and knee replacement: A 15-year retrospective cohort study of routine clinical practice. Bone Joint J 2014; 96-B(4):479-485. PMID: 24692614.

28. An VV, Phan K, Levy YD, Bruce WJ. Aspirin as thromboprophylaxis in hip and knee arthroplasty: A systematic review and meta-analysis. J Arthroplasty 2016; 31(12):2608-2616. PMID: 27178011.

29. Wilson DG, Fode WE, Chauhan SK, Rogers BA. Systematic review of aspirin for thromboprophylaxis in modern elective total hip and knee arthroplasty. Bone Joint J 2016; 98-B(8):1056-1061. PMID: 27482017.

30. Jones CW, Spasojevic S, Gol G, Joseph Z, Wood DJ, Yates PJ. Wound discharge after pharmacological thromboprophylaxis in lower limb arthroplasty. J Arthroplasty 2018; 33(1):224-229. PMID: 28869115.

31. Faour M, Puzzioli NS, Brigati DP, et al. Low-dose aspirin is safe and effective for venous thromboembolism prophylaxis following total knee arthroplasty. J Arthroplasty 2018; 33(7):S131-S135. PMID: 29656974.

32. Parvizi J, Huang R, Restrepo C, et al. Low-dose aspirin is effective chemoprophylaxis against clinically important venous thromboembolism following total joint arthroplasty: A preliminary analysis. J Bone Joint Surg Am 2017; 99(2):91-98. PMID: 28099298.

33. Gomez-Outes A, Terleira-Fernandez AI, Calvo-Rojas G, Suarez-Gea ML, Vargas-Castrillon E, Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: A systematic review and meta-analysis of subgroup. Thrombos 2013; 2013:640723. PMID: 24455237.

34. Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003; 107(23 Suppl 1):I9-16. PMID: 12814980.

35. Parvizi J, Huang R, Restrepo C, et al. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: Findings from the Global Orthopaedic Registry. J Bone Joint Surg Br 2007; 89(6):799-807. PMID: 17013508.

36. Wolowczak SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI. Efficacy and safety of dabigatran exetilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost 2009; 101(1):77-85. PMID: 19123192.

37. Li J, Wang X, Sun M, Yan G. "Rebound" hypercoagulability after interruption of anticoagulation in patients with atrial fibrillation. Int J Cardiol 2018; 271:119. PMID: 30223341.

38. Haynes LM, Orfeo T, Mann KG. Rivaroxaban delivery and reversal at a routine oral dose: A 15-year retrospective cohort study of routine clinical practice. Bone Joint J 2016; 98-B(8):1056-1061. PMID: 27482017.

39. Haemost 2009; 101(1):77-85. PMID: 17613508.

Keywords: deep venous thrombosis, pulmonary embolism, venous thromboembolism, bleeding, total knee arthroplasty.